Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 11,335 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Interventions: docetaxel, oxaliplatin, vandetanib, placebo; Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepatocellular Carcinoma
Interventions: Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE); Drug · Other · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 24
States / cities: Costa Mesa, California • La Jolla, California • Orange, California + 19 more

Conditions: Postoperative Atrial Fibrillation
Interventions: Amiodarone, DC-cardioversion, Rate Control; Drug · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more

Conditions: Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
Interventions: Olanzapine, risperidone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 40 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 24
States / cities: Stanford, California • Miami, Florida • Atlanta, Georgia + 21 more

Conditions: Obesity
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 20 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Epilepsy
Interventions: ReBOOT program; Behavioral
Lead sponsor: Kayela Arrotta; Other
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Persistent Disease, Recurrent Cervical Carcinoma
Interventions: Brivanib Alaninate, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 43
States / cities: Phoenix, Arizona • Burbank, California • San Francisco, California + 37 more

Conditions: Pregnancy Preterm, Pregnancy Prom, PROM, Preterm (Pregnancy), PROM (Pregnancy), Premat Rupture Membranes Preterm Unspec to Length of Time Between Rupture/Labor, Premature Birth
Interventions: Azithromycin Pill, Amoxicillin Pill; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Cleveland, Ohio

Conditions: Lumbosacral Radiculopathy
Interventions: Clonidine Micropellets, Sham; Combination Product · Other
Lead sponsor: Sollis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 33
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more

Conditions: Prostate Cancer
Interventions: magnetic resonance imaging, prostate biopsy; Device · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Carcinoma, Renal Cell, Kidney Neoplasms
Interventions: ZD6126, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 16
States / cities: Los Angeles, California • Newark, Delaware • Tampa, Florida + 13 more

Conditions: Cardiac Rehabilitation
Interventions: Fit Bit Blaze, Garmin Forerunner 235, Tom Tom Spark Cardio, Apple Watch; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type2 Diabetes, Dyslipidemia
Interventions: K-877, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10,544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 242
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 192 more

Conditions: HIV Infections
Interventions: lopinavir/ritonavir, lamivudine/zidovudine, efavirenz, lamivudine, stavudine, zidovudine, didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 32
States / cities: Los Angeles, California • Denver, Colorado • Farmington, Connecticut + 19 more

Conditions: Meningitis, Meningococcal Infection
Interventions: MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus; Biological
Lead sponsor: Novartis; Industry
Eligibility: 55 Days to 89 Days
Enrollment: 7,744 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 130
States / cities: Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more

Conditions: Acute Ischemic Stroke
Interventions: NeuroThera® Laser System; Device
Lead sponsor: PhotoThera, Inc; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 26
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Encinitas, California + 23 more

Conditions: Spinal Cord Injury
Interventions: Surgery, IRS-8; Procedure · Device
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2016
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
Interventions: PY314, Combination Therapy: PY314 + Pembrolizumab; Drug
Lead sponsor: Ikena Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 23
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more

Conditions: Colorectal Neoplasms
Interventions: Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 989
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Vedolizumab IV, No Intervention; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 2 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 22
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Myopic Astigmatism
Interventions: Visian TICL; Device
Lead sponsor: Staar Surgical Company; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Honolulu, Hawaii • Indianapolis, Indiana • Bowie, Maryland + 5 more

Conditions: Periodontitis, Diabetes Mellitus Type 2
Interventions: local antibiotic application of topical minocycline, Scaling and Root Planing; Drug · Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Catheter-Associated Urinary Tract Infection
Interventions: Bactrim, Placebo; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Inflammatory Bowel Disease, Intestinal Fistula
Interventions: AST-120; Drug
Lead sponsor: Ocera Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 25
States / cities: Anaheim, California • San Carlos, California • Winter Park, Florida + 20 more

Search by objective public record fields.

Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

CAFE Comparison of Atypicals in First Episode of Psychosis

Evaluation of High-Density Lipoprotein in Obesity Study

Readiness Brain Operation Optimization Training (ReBOOT) for Epilepsy Surgery

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age

Treatment of Pain Associated With Lumbosacral Radiculopathy in Adults

MRI Before Biopsy in Diagnosing Patients With Prostate Cancer

Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

Accuracy of Commercially Available Heart Rate Monitors III

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)

Study of an Implantable Functional Neuromuscular Stimulation System for Patients With Spinal Cord Injuries

A Study of PY314 in Subjects With Advanced Solid Tumors

S0820, Adenoma and Second Primary Prevention Trial

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

STAAR Visian Toric ICL Post-Approval Study

Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics

Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas